Ustekinumab biotherapy and real-time psoriasis capacitance mapping: a pilot study.

Area of Science:

• Dermatology and Bioengineering
• Medical Imaging and Diagnostics

Background:

• Moderate to severe psoriasis treatment has advanced with targeted biologicals.
• Accurate assessment of disease severity and treatment response is crucial for these therapies.
• Bioengineering-developed dermometrology offers objective, quantitative disease assessment methods.

Purpose of the Study:

• To evaluate psoriasis capacitance mapping (PCM) as a method for assessing treatment efficacy.
• To determine if PCM can quantify changes in lesional skin due to biologic therapy.
• To explore PCM's utility in evaluating the anti-inflammatory effects of ustekinumab.

Main Methods:

• Psoriasis capacitance mapping (PCM) was employed to assess skin scaliness and stratum corneum water content.
• PCM was used on target lesions of five patients with moderate to severe psoriasis.
• Therapeutic effects of ustekinumab were monitored over a one-month treatment period.

Main Results:

• A reduction in inflammatory dampness within the stratum corneum was observed after one month of ustekinumab treatment.
• PCM successfully visualized changes in lesional skin characteristics.
• The study demonstrated the potential of PCM in tracking therapeutic responses.

Conclusions:

• Psoriasis capacitance mapping (PCM) shows promise as a rapid and convenient tool for evaluating anti-inflammatory efficacy.
• PCM can be utilized for assessing ustekinumab and other biologic therapies in psoriasis.
• This pilot study supports PCM's role in objective disease management and treatment monitoring.